BioSpace News Archive

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis in the knee and potentially other articular joints, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2021.

Avinger, Inc., a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease, announced it has regained compliance with Nasdaq listing requirements.

Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), and Organo Therapeutics, announced today they have entered into a collaboration agreement to work toward accelerating the discovery of drugs for the treatment of Parkinson’s Disease.

RNAimmune, Inc. (the “Company” or “RNAimmune”), a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, announced today that is has secured an approximately US$27 million Series A round of financing.

ASC Therapeutics, a privately held biopharmaceutical company pioneering the development of transformative in-vivo gene replacement, gene editing and allogeneic cell therapies for hematologic, metabolic, and other rare diseases has received from the United States (U.S.) Food and Drug Administration (FDA) the Fast Track Designation for ASC618, a second-generation gene therapy of hemophilia A.

ShouTi Inc., a clinical-stage global biopharmaceutical company developing novel oral therapeutics to treat a wide range of chronic diseases, announced the appointment of Sharon Tetlow to the company’s board of directors.

Australian biotech company Noxopharm (ASX:NOX) has announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to Veyonda ® , its lead oncology drug candidate , for use in the treatment of soft tissue sarcoma.

Pharvaris today reported financial results for the fourth quarter and year ended December 31, 2021 and provided recent business highlights.

Aldeyra Therapeutics, Inc. today will announce at its 2022 Research & Development Day that three clinical trials of ADX-629, a first-in-class orally administered RASP modulator, generated signs of pharmacodynamic and clinical activity consistent with broad-based reduction in pathologic inflammation.

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced dosing of the first patient in the Phase 1/2 STEADFAST clinical study evaluating TX200, a wholly-owned autologous Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation from a living donor.